NovaBridge Biosciences (NBP) H.C. Wainwright “HCW@Home” series summary

Corporate transformation and strategic focus

• Underwent significant restructuring, divesting China operations to focus on a U.S.-based, capital-efficient model with a lean team of five employees.

• Pipeline now centers on three clinical-stage assets, with primary emphasis on the Claudin 18.2/4-1BB bispecific antibody (Givastomig, or Giva).

• Financially positioned with $168 million in cash as of Q1, supporting key clinical milestones over the next 6–12 months.

Clinical development and data highlights

• Giva is being developed as an add-on to standard frontline therapy (IO plus chemotherapy) for metastatic gastric cancer, without altering the existing regimen.

• Monotherapy studies showed an 18% ORR in heavily pretreated patients with a favorable safety profile; combination studies report promising efficacy and safety in 17-patient dose escalation.

• Giva targets a significant unmet need, with metastatic gastric cancer having a 7% five-year survival rate and representing a $12 billion addressable market in the U.S., EU, and Japan.

Scientific rationale and differentiation

• Claudin 18.2 is selectively exposed on tumor cells due to loss of cell polarity, enabling precise targeting with minimal off-tumor toxicity.

• Giva’s conditional 4-1BB activation is restricted to the tumor microenvironment, reducing risks of systemic immune activation and hepatotoxicity seen with other 4-1BB agonists.

• Demonstrates activity in tumors with low Claudin 18.2 expression, expanding potential patient eligibility.